+68% Type I Collagen

Confirmed via punch biopsy at week 8 post-treatment. Sustained synthesis maintained through month 12. [1]

+52% Elastin Synthesis

Measured by histological analysis. Significant improvement in dermal elasticity matrix and tensile strength. [1]

12-15 Month Longevity

Controlled polymer degradation pathway ensures steady neocollagenesis before complete bio-resorption into CO2 and H2O.

Composition Data

• PCL Concentration: 20% w/v
• PCL Particle Size: 25-50 μm (optimized to prevent phagocytosis)
• Carrier Gel: PBS-based CMC (Carboxymethyl Cellulose)
• pH Level: 6.8 – 7.2
• Sterilization: 0.22μm terminal filtration

Administration Protocol

• Depth: Deep dermal / Subdermal plane
• Device: 25G or 27G microcannula required
• Dosage: 0.05ml – 0.1ml per injection point
• Regimen: 3 sessions spaced 4 weeks apart
• Storage: 2°C to 25°C. Do not freeze.